The soft tissue sarcoma with lung metastases market across the 7MM is projected to demonstrate steady growth during the 2026–2036 forecast period, driven primarily by the anticipated launch of novel therapies such as Annamycin (Moleculin), IP-001 (Immunophotonics), Fibromun (Philogen), Lifileucel (Iovance Biotherapeutics), Chiauranib (Chipscreen), LVGN6051 (Lyvgen), and others, and expanding therapeutic adoption in advanced disease settings.

LAS VEGAS, May 26, 2026 /PRNewswire/ -- Recently published Soft Tissue Sarcoma with Lung Metastases Market Insights report includes a comprehensive understanding of current treatment practices, soft tissue sarcoma with lung metastases emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Soft Tissue Sarcoma with Lung Metastases Market Summary

• The total soft tissue sarcoma with lung metastases treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest soft tissue sarcoma with lung metastases treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• STS represents a meaningful oncologic burden, with approximately 14,000 new cases diagnosed annually in the US. Notably, up to 50% of these patients eventually develop lung metastases, highlighting the substantial progression risk and the clinical impact of STS-LM.
• Leading soft tissue sarcoma with lung metastases companies, such as Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen, and others, are developing new soft tissue sarcoma with lung metastases treatment drugs that can be available in the soft tissue sarcoma with lung metastases market in the coming years. 
• The promising soft tissue sarcoma with lung metastases therapies in clinical trials include Annamycin, IP-001, Fibromun, Lifileucel, Chiauranib, LVGN6051, and others.

Discover what are promising targeted therapies for metastatic sarcoma @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market

Key Factors Driving the Growth of the Soft Tissue Sarcoma with Lung Metastases Market 

• Rising Incidence of Soft Tissue Sarcoma and Metastatic Cases: The growing incidence of soft tissue sarcoma worldwide is a primary driver of market growth. Lung metastases occur in a significant proportion of patients with high-grade sarcomas, often representing the most common site of distant spread.
• Advancements in Targeted Therapies and Immunotherapy: Rapid progress in targeted therapies, tyrosine kinase inhibitors (TKIs), and immunotherapies has transformed the treatment landscape for metastatic STS. These therapies provide improved disease control and survival outcomes compared with traditional chemotherapy, encouraging wider adoption and driving market growth.
• Increasing Focus on Precision Medicine: The integration of molecular profiling and biomarker-driven treatment strategies has accelerated the shift toward personalized oncology.
• Growing Clinical Trial Activity: The dynamics of the STS-LM market are expected to change in the coming years due to the launch of emerging therapies such as Annamycin (Moleculin), IP-001 (Immunophotonics), Fibromun (Philogen), Lifileucel (Iovance Biotherapeutics), Chiauranib (Chipscreen), LVGN6051 (Lyvgen), and others.

Ramandeep Singh, Senior Consultant of Forecasting and Analytics at DelveInsight, pointed out that a key unmet aspect specific to STS-LM is the limited availability of therapies that effectively target pulmonary metastatic disease without compromising lung function. Disease control in the lungs remains challenging, and progression within the pulmonary compartment is often the primary cause of clinical deterioration, highlighting the need for lung-focused and metastasis-directed therapeutic strategies.

Soft Tissue Sarcoma with Lung Metastases Market Analysis

• Systemic pharmacological strategies for soft tissue sarcoma with lung metastases primarily aim to control widely spread pulmonary disease and slow progression in advanced stages. 
• Advanced cellular therapies such as TECELRA (afamitresgene autoleucel) represent a targeted treatment option for eligible patients with metastatic synovial sarcoma. 
• In parallel, investigational therapies like IP-001 and Annamycin, along with other pipeline candidates, highlight continued efforts to broaden and improve systemic therapeutic options for this highly aggressive condition.
• Non-pharmacological interventions also play a critical role in managing STS-LM. Surgical removal of lung metastases remains the most established approach for carefully selected patients with limited and operable disease. 
• Pulmonary metastasectomy is intended to completely remove metastatic nodules and has the potential to provide significant survival advantages in appropriately chosen cases. 
• When surgery is not possible, other local treatment strategies, such as stereotactic body radiotherapy (SBRT) or minimally invasive ablative procedures, may be used to achieve localized control of tumors within the lungs.
• Taken together, the management of STS-LM relies on a multidisciplinary and personalized treatment strategy. 
• Clinicians must balance systemic therapies that address widespread disease with localized interventions that target lung metastases. 
• Achieving the best outcomes often depends on factors such as patient selection, tumor biology, and optimal sequencing of treatments, emphasizing the importance of combining innovative systemic therapies with established lung-directed approaches to manage tumor burden and disease progression effectively.

Soft Tissue Sarcoma with Lung Metastases Competitive Landscape

Some of the STS-LM drugs under development include Annamycin (Moleculin), IP-001 (Immunophotonics), Fibromun (Philogen), Lifileucel (Iovance Biotherapeutics), Chiauranib (Chipscreen), LVGN6051 (Lyvgen), and others.

Moleculin's Annamycin is an investigational next-generation anthracycline being developed by Moleculin to address multidrug resistance. It utilizes a lipid-based delivery system to improve tumor accumulation while minimizing cardiotoxicity. The therapy is being explored for aggressive and treatment-resistant cancers, including certain sarcomas and hematologic malignancies. It is currently undergoing Phase I/II clinical trials.

Immunophotonics' IP-001 is an experimental intratumoral immunotherapy developed by Immunophotonics for the treatment of soft tissue sarcoma. The therapy uses a photothermal approach to trigger localized tumor destruction while also promoting systemic anti-tumor immune activity. It is being investigated for advanced and refractory sarcoma indications. At present, IP-001 is in Phase I/II clinical development for non-small cell lung cancer (NSCLC) and soft tissue sarcoma (STS), with Phase I enrollment for STS already completed.

Philogen's Fibromun (L19TNF) is a fully human immunomodulatory agent composed of the L19 antibody fused with TNF, a potent pro-inflammatory cytokine. To date, recombinant TNF has received approval only for a limited number of clinical indications.

The anticipated launch of these emerging therapies are poised to transform the soft tissue sarcoma with lung metastases market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the soft tissue sarcoma with lung metastases market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about what drugs are in development for metastatic soft tissue sarcoma @ Soft Tissue Sarcoma with Lung Metastases Drugs

What is Soft Tissue Sarcoma with Lung Metastases?

Soft tissue sarcoma with lung metastases refers to a stage of soft tissue sarcoma in which the malignant tumor that originates in the body's connective tissues, such as muscle, fat, nerves, blood vessels, or fibrous tissue, has spread beyond its primary site to the lungs. Soft tissue sarcomas are rare cancers that typically develop in the arms, legs, trunk, or retroperitoneum. When cancer cells break away from the primary tumor, they can travel through the bloodstream and form secondary tumors in distant organs, with the lungs being the most common site of metastasis. Lung metastases may remain asymptomatic in early stages but can eventually lead to symptoms such as persistent cough, shortness of breath, chest pain, or fatigue. The presence of lung metastases generally indicates advanced disease and significantly influences treatment strategies, which may include systemic therapies such as chemotherapy, targeted therapy, immunotherapy, or surgical removal of metastatic lung nodules in selected patients. Prognosis depends on factors such as the sarcoma subtype, number and size of lung lesions, and the patient's overall health.

Soft Tissue Sarcoma with Lung Metastases Epidemiology Segmentation

The soft tissue sarcoma with lung metastases epidemiology section provides insights into the historical and current soft tissue sarcoma with lung metastases patient pool and forecasted trends for the leading markets. In France, around 4,000 new STS cases are diagnosed each year, reflecting the biological heterogeneity of STS, its broad anatomical distribution, and the continued challenges in early detection that lead to sustained annual case identification across multiple subtypes.

The soft tissue sarcoma with lung metastases treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of STS
• Total Incident Cases of STS-LM
• Gender-specific Incident Cases of STS-LM

Scope of the Soft Tissue Sarcoma with Lung Metastases Market Report

• Therapeutic Assessment: Soft Tissue Sarcoma with Lung Metastases current marketed and emerging therapies
• Soft Tissue Sarcoma with Lung Metastases Market Dynamics: Key Market Forecast Assumptions of Emerging Soft Tissue Sarcoma with Lung Metastases Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement

Download the report to understand what are promising targeted therapies for metastatic sarcoma @ Soft Tissue Sarcoma with Lung Metastases Market Analysis

Table of Contents

Related Reports

Soft Tissue Sarcoma Market

Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key soft tissue sarcoma companies, including Gem Pharmaceuticals, Lytix Biopharma, Incyte Corporation, Daiichi Sankyo, NantPharma, Iovance Biotherapeutics, Agenus, Eli Lilly and Company, Adaptimmune, Aadi, AVEO Pharmaceuticals, Amgen, and others.

Soft Tissue Sarcoma Clinical Trial Analysis 

Soft Tissue Sarcoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key STS companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Osteosarcoma Market

Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies including Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others.

Ewing Sarcoma Market

Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies including Salarius Pharmaceuticals, Jazz Pharmaceuticals And Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/soft-tissue-sarcoma-with-lung-metastases-market-set-to-expand-across-the-7mm-during-the-forecast-period-20262036-with-advancing-targeted-and-cellular-therapies--delveinsight-302781508.html

SOURCE DelveInsight Business Research, LLP